Replies to post #146957 on Biotech Values

[DewDiligence]

PPHM—There is no way of knowing if dual action [MoA] actually occurred in human trials. One way to look at is via adverse event to see if they show up. I haven't seen much indication from adverse events indicating either anti-angiogenic activity or immune response.

Excellent point. To date, the adverse-event profile of Bavituximab is more consistent with its being a placebo than the highly active agent in such disparate diseases as HCV, HIV, and multiple forms of cancer that the company’s management would have investors believe.

[biomaven0]

There is no way of knowing if dual action actually occurred in human trials.

Well it's likely not that potent on either front compared with say Avastin or anti-CTL4 so I'm not that surprised that not much in the way of side effects. Of course that's very much a double-edged sword.

They should be able to tell if there is indeed an M1 to M2 macrophage switch in the clinic.

Peter